ISIN:SE0007784319

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

LUND, Sweden, Nov. 25, 2020 /PRNewswire/ -- RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company's drug candidate, RV001. Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate ...

2020-11-25 16:06 794

Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer

STOCKHOLM, Nov. 13, 2020 /PRNewswire/ -- RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac's drug candidate ...

2020-11-13 17:53 1258

RhoVac Participates in BIO Europe Digital

LUND, Sweden, Oct. 26, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that it is participating this week in the partnering event BIO Europe 2020 Digital. This week the digital version of the massive pharmaceutical partnering conference BIO Europe is held with participation from RhoVac...

2020-10-26 16:26 683

Article on RhoVac's Phase I/II study to be published in November

LUND, Sweden, Oct. 26, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that the publication of the article on RhoVac's Phase I/II study is set to be published in November. As previously disclosed, the article elaborating on the results of RhoVac's Phase I/II study in prostate cancer in...

2020-10-26 15:51 724

The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study

LUND, Sweden, Oct. 12, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002 ("BRaVac"), is expected to be further delayed due to the prevailing Covid-19 pandemic. The recruitm...

2020-10-12 15:03 1595

First patient in treatment in RhoVac's clinical phase IIb study in Sweden

STOCKHOLM, Sept. 17, 2020 /PRNewswire/ --  RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...

2020-09-17 23:51 2669

RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4th 2020,  that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing ProfessorGeorg Hollaender, Action Research Professor and Head of Department at Oxford ...

2020-09-04 17:35 3025

First patient in treatment in RhoVac's clinical phase IIb study in the USA

STOCKHOLM, Aug. 10, 2020 /PRNewswire/ -- The first patient in the USA is included in RhoVac's clinical phase IIb study, called BRaVac. The first US clinic to include a patient in the study was Carolina Urologic Research Center. BraVac is a randomized, placebo controlled and double-blind study, wi...

2020-08-10 16:47 1348

A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac")  is published in the June edition of MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in RhoVac's achievements as well as plans for t...

2020-07-01 20:41 1038

RhoVac Marketed in International Press

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...

2020-07-01 15:49 827

First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany

STOCKHOLM, April 24, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). The first patient in Germany is in treatment...

2020-04-24 00:37 1224

Covid-19 Related Delays in the Ongoing Phase IIb-study are Expected to be Managed With Existing Funding

STOCKHOLM, April 2, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, onApril 2 2020, that the company is now seeing signs of delays in the ongoing clinical phase IIb study with the drug candidate RV001 in prostate cancer, due to the Covid-19 pandemic. However, the company believes that ...

2020-04-02 17:17 855

RhoVac Announces Appointment of Professor Anne J. Ridley to its Scientific Advisory Board

STOCKHOLM, Feb. 6, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 6 th February 2020, the appointment of a leading oncology expert to its Scientific Advisory Board with the addition ofAnne J. Ridley, PhD, Professor of Cell Biology and Head of School of Cellular and Molecular Medicine, ...

2020-02-06 20:22 715

RhoVac Reports Interim Results on Immunological Response with RV001

STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- Today, 18th November 2019, RhoVac AB ("RhoVac") reports interim results from ongoing immunological studies at University of Tübingen,Germany concluding that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells. In July 2019 RhoVac publishe...

2019-11-18 17:13 545